First and foremost, **TOTAL RAZZAQ DOES NOT PROMOTE WEED/CANNABIS IN ANY FORM OR USAGE **
SPOILER ALERT: Smoking anything is not healthy. THC (the part of weed that gets you high) is not healthy for most mental health conditions. For sure, there are benefits for certain conditions, like easing pain from chemo or cataract.
Gobsmacked is a Total-Razzaq clothing collection intended to educate how you can naturally better you mental health. Total Razzaq's Gobsmacked collection should not be interpreted as a "smoke weed everyday message". This collection's mission should be understood as, “CBD helps with depression, anxiety & other more serious mental health problems", but why is it illegal?
This particular collection (seen below) displays this message on our apparel. Our shirts are interactive. A QR code links the shirt to this educational blog and the website. This is what the CBD "Gobsmacked" collection looks like.
This blog provides unbiased cannabis health effects. "The National Academics of Press" institution's research is what was used as reference and can be downloaded using the link in this paragraph. I summarized the report's mental health effect findings from cannabis use. Fact based research was derived from the 2017 NAP publication and can be found here.
National Academies of Sciences, Engineering, and Medicine is the institution, from which Total Razzaq's cannabis effects on mental has been derived. The report covers a range of cannabis subjects i.e. Policy/laws, health effects for specific ailments (physical and mental).
Mental health is of course the focus of this summary. Here are highlights:
* Cannabis use is likely to increase the risk of developing schizophrenia and other psychoses; the higher the use the greater the risk.
* Individuals with history of schizophrenia and other psychoses, cannabis use may be linked to better performance on learning and memory tasks.
* CBD use does not appear to increase the likihood of depression, anxiety and PTSD.
* Bipolar -- near daily use may increase stronger symptoms
* Regular cannabis use is likely to increase social anxiety
To date, more than 104 different cannabinoids1 have been identified in cannabis (ElSohly and Gul, 2014). Other compounds identified include terpenoids, flavonoids, nitrogenous compounds, and more common plant molecules (American Herbal Pharmacopoeia, 2013). Among these, D9-tetrahydrocannabinol (THC) has received the most attention for being responsible for the intoxicated state sought after by recreational cannabis users, owing to its ability to act as a partial agonist2 for type-1 cannabinoid (CB1) receptors. Cannabinoids exist mainly in the plant as their carboxylic precursors (D9-tetrahydrocannabinolic acid [THCA] and cannabidiolic acid [CBDA]) and are decarboxylated by light or heat while in storage or when combusted (Grotenhermen, 2003). D9-THC is synthesized within the glandular trichomes present in the flowers, leaves, and bracts of the female plant. It shares a common precursor, olivetoic acid, with another quantitatively important constituent of Cannabis sativa, cannabidiol (CBD), which is the most abundant cannabinoid in hemp (see Figure 2-1). For this reason, the genetic profile and relative level of expression of the enzymes responsible for their synthesis (genotype), namely THCA synthase and CBDA synthase, determine the chemical composition of a particular cultivar (chemotype). Cannabis plants typically exhibit
CBD is also a known agonist of serotonin 5-HT1A receptors (Russo et al., 2005) and transient receptor potential vanilloid type 1 (TRPV1) receptors (Bisogno et al., 2001). It can also enhance adenosine receptor signaling by inhibiting adenosine inactivation, suggesting a potential therapeutic role in pain and inflammation (Carrier et al., 2006). The antioxidant and anti-inflammatory properties of this compound may explain its potential neuroprotective actions (Scuderi et al., 2009). Irrespective of the mechanism of action, there is evidence that CBD could potentially be exploited in the treatment and symptom relief of various neurological disorders such as epilepsy and seizures (Hofmann and Frazier, 2013; Jones et al., 2010), psychosis (Leweke et al., 2016), anxiety (Bergamaschi et al., 2011), movement disorders (e.g., Huntington’s disease and amyotrophic lateral sclerosis) (de Lago and Fernandez-Ruiz, 2007; Iuvone et al., 2009), and multiple sclerosis (Lakhan and Rowland, 2009).
Non-THC laws permit the use of no-THC or low-THC/high-CBD products, such as CBD oil, to treat a short list of qualifying conditions, such as refractory epilepsy. This category is by far the most restrictive, and states that adopt these non-THC policies generally prohibit the supply and distribution of such products, granting only a legal defense for their use.